Zhittya (meaning Life in Ukrainian) is a biotechnology company based in Las Vegas, Nevada. We are seeking to commercialize human FGF-1, a potent, naturally occurring growth factor.
Since its discovery in the 1970s, FGF-1 has been extensively studied. Since 1998, Daniel Montano, Viktoriya Tamlenova-Montano, and Dr. Jack Jacobs have been working to bring this drug to market.
Zhittya's management believes that FGF-1 has the potential to be a revolutionary new biological drug for the treatment of numerous diseases characterized by a lack of blood flow to an organ or tissue.
In fact, there are over 75 human diseases resulting from a lack of blood flow or perfusion to tissues, and Zhittya has now targeted 19 of those disorders for treatment with FGF-1
